240 related articles for article (PubMed ID: 32602383)
1. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis.
Fu Z; Xu Y; Cai C
J Asthma; 2021 Oct; 58(10):1350-1358. PubMed ID: 32602383
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
6. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
Teach SJ; Gill MA; Togias A; Sorkness CA; Arbes SJ; Calatroni A; Wildfire JJ; Gergen PJ; Cohen RT; Pongracic JA; Kercsmar CM; Khurana Hershey GK; Gruchalla RS; Liu AH; Zoratti EM; Kattan M; Grindle KA; Gern JE; Busse WW; Szefler SJ
J Allergy Clin Immunol; 2015 Dec; 136(6):1476-1485. PubMed ID: 26518090
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience.
Giubergia V; Ramírez Farías MJ; Pérez V; Crespi N; Castaños C
Arch Argent Pediatr; 2019 Apr; 117(2):e115-e120. PubMed ID: 30869489
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
[TBL] [Abstract][Full Text] [Related]
10. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
11. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
Rodrigo GJ; Neffen H
Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
[TBL] [Abstract][Full Text] [Related]
12. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on omalizumab in allergic asthma.
Bang LM; Plosker GL
BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
[TBL] [Abstract][Full Text] [Related]
14. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
[TBL] [Abstract][Full Text] [Related]
15. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.
Chauhan BF; Chartrand C; Ducharme FM
Cochrane Database Syst Rev; 2013 Feb; (2):CD009611. PubMed ID: 23450606
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
18. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
[TBL] [Abstract][Full Text] [Related]
19. A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients.
Domingo C; Pomares X; Navarro A; Amengual MJ; Montón C; Sogo A; Mirapeix RM
Br J Clin Pharmacol; 2018 Feb; 84(2):339-348. PubMed ID: 29044640
[TBL] [Abstract][Full Text] [Related]
20. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.
Chauhan BF; Chartrand C; Ducharme FM
Cochrane Database Syst Rev; 2012 Dec; 12():CD009611. PubMed ID: 23235678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
